Mafb mutations in multicentric carpo-tarsal OSTEOLYSIS (MCTO): multi-omic exploration of the mechanisms involved in skeletal OSTEOLYSIS in a mouse MCTO model - multicentric carpo-tarsal OSTEOLYSIS…
Active Grant Awarded
- Award ID
- R21AR087046
- Recipient
-
President And Fellows Of Harvard College UEI JDLVAVGYJQ21 Part of Harvard College President & Fellows Of
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $395,038
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 9% complete
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health, through its National Institute of Arthritis and Musculoskeletal and Skin Diseases, awarded a grant of $395,038 to President and Fellows of Harvard College, doing business as Harvard Medical School, on September 17, 2026, under Assistance Listing 93.846, Arthritis, Musculoskeletal and Skin Diseases Research.
The award funds a multi-omic research project on the mechanisms of skeletal osteolysis in multicentric carpo-tarsal osteolysis (MCTO), an ultra-rare autosomal dominant skeletal dysplasia caused by single amino acid substitutions in the MAFB transactivation domain. The project proposes to use a novel MAFB knock-in mouse model carrying the Pro59Leu mutation found in MCTO patients, which the source states reproduces most MCTO clinical features, including bone loss and carpo-tarsal subchondral resorption. The stated objective is to elucidate how MAFB mutations induce spatially restricted osteolysis, a mechanism the source says has not been elucidated.
Work is performed in Boston, Massachusetts 02115. The period of performance runs from the September 17, 2026 award date to an ultimate completion date of August 31, 2028. The assistance type is a grant.
Description
Mafb mutations in multicentric carpo-tarsal OSTEOLYSIS (MCTO): multi-omic exploration of the mechanisms involved in skeletal OSTEOLYSIS in a mouse MCTO model - multicentric carpo-tarsal OSTEOLYSIS (MCTO; omim 166300; orpha: 2774; gard: 13042), is an ultra-rare autosomal dominant skeletal dysplasia that presents in early childhood with joint pain and swelling and is characterized by the progressive disappearance (OSTEOLYSIS) of carpal and tarsal bones, but bone destruction also affects other parts of the skeleton (e.g. shoulders, elbows, knees and cervical spine). Affected individuals also present with subtle craniofacial abnormalities, and many develop glomerulosclerosis with progressive loss of podocyte foot processes, with proteinuria and chronic renal insufficiency. MCTO is due to single amino acid substitutions in a specific 51 AA area of the transactivation domain of mafb. The mechanisms by which mafb mutations induce partially spatially restricted OSTEOLYSIS and bone disappearance have not been elucidated. Even though MCTO appears to be the result of enhanced bone resorption (OSTEOLYSIS), treatment of MCTO patients with anti-resorptive drugs lacks efficacy, leaving the affected children with a poor prognostic. MCTO is frequently MIS-diagnosed for juvenile idiopathic arthritis but although patients with MCTO report relief of joint pain with anti-inflammatories, these have also failed to prevent bone loss. Thus, although bone resorption is a component of MCTO's pathological mechanism, blocking bone resorption or inflammation does not stop the rapid bone loss in these patients, particularly in the hands, feet, elbows and knees. This implies that more complex molecular and cellular mechanisms are at play. Here we propose to use a novel mafb knock-in mouse model harboring one of the mafb mutations found in MCTO patients (PRO59LEU), which we show here reproduces most of the MCTO clinical features, including bone loss and carpo-tarsal subchondral resorption. Our preliminary data revealed contrasting changes in primary cells in vitro and in vivo, supporting our hypothesis that the observed local and systemic bone loss are the result of changes in the bone/bone marrow microenvironment, and possibly of the joint as well. Our proposed mix of targeted and unbiased transcriptomic and proteomic approaches aims at identifying the microenvironmental and cellular changes that occur in the skeletal system because of MCTO mafb mutations. For this purpose, we will perform unbiased genome-wide exploration of the entire skeletal cellular micro-environment, including articular cartilage, synovium, cortical bone (with osteocytes) and bone marrow as well as individual primary cell types that may play a role in this disease (osteoblasts, bone marrow macrophages, osteoclasts). We will also explore the changes in bone, in serum and bone marrow cytokines/hormones and in mafb-DNA binding sites to help reveal the underlying transcriptional mechanisms involved in MCTO. Unbiased genome-wide explorations of the same cell populations will identify altered gene profiles and cytokine signaling pathways in specific cell types. These studies will provide mechanistic insights into MCTO, opening novel therapeutic approaches, a significant breakthrough given that all attempts at stopping or reversing bone loss in these patients have failed.
Quick answers
Who received award R21AR087046?
R21AR087046 was awarded to President And Fellows Of Harvard College by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 17, 2026.
How much is award R21AR087046 worth?
$395,038 has been obligated on R21AR087046.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award